健帆生物
(300529)
| 流通市值：115.53亿 | | | 总市值：178.95亿 |
| 流通股本：5.21亿 | | | 总股本：8.08亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,485,982,086 | 1,012,143,747.49 | 572,557,659.76 | 2,491,439,432.1 |
| 营业收入 | 1,485,982,086 | 1,012,143,747.49 | 572,557,659.76 | 2,491,439,432.1 |
| 二、营业总成本 | 1,013,972,529.49 | 705,759,297.71 | 350,485,573.54 | 1,550,044,568.16 |
| 营业成本 | 287,351,394.41 | 196,862,921.61 | 112,107,850.34 | 440,106,205.75 |
| 税金及附加 | 23,408,124.83 | 15,705,119.57 | 8,513,231.6 | 35,071,028.84 |
| 销售费用 | 441,051,536.95 | 323,580,411.95 | 156,935,831.02 | 700,633,371.25 |
| 管理费用 | 112,650,002.54 | 72,906,022.94 | 27,613,452.84 | 138,145,808.75 |
| 研发费用 | 176,357,010.23 | 114,619,565.49 | 54,023,867.54 | 253,908,240.42 |
| 财务费用 | -26,845,539.47 | -17,914,743.85 | -8,708,659.8 | -17,820,086.85 |
| 其中:利息费用 | 40,293,049 | 25,227,139.34 | 12,250,503.89 | 36,044,032.88 |
| 其中:利息收入 | 66,998,197.85 | 43,407,634.42 | 21,464,347.46 | 53,262,357.84 |
| 加:公允价值变动收益 | 0 | 0 | 0 | -14,985.01 |
| 加:投资收益 | 0 | 0 | 0 | 10,524,343.46 |
| 资产处置收益 | 5,915,870.73 | 6,056,875.34 | 5,495,464.11 | 864,771.99 |
| 资产减值损失(新) | 0 | 0 | 0 | -6,511,909.58 |
| 信用减值损失(新) | 2,448,540.08 | 3,970,098.57 | 777,074.26 | 1,957,815.76 |
| 其他收益 | 34,755,288.89 | 23,112,198.66 | 10,834,859.72 | 81,239,920.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 515,129,256.21 | 339,523,622.35 | 239,179,484.31 | 1,029,454,821.02 |
| 加:营业外收入 | 319,563.54 | 246,019.54 | 166,451.17 | 371,634.34 |
| 减:营业外支出 | 16,559,805.75 | 10,705,253.57 | 7,667,030.79 | 13,018,453.85 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 498,889,014 | 329,064,388.32 | 231,678,904.69 | 1,016,808,001.51 |
| 减:所得税费用 | 78,452,712.57 | 53,861,287.1 | 36,428,218.3 | 135,889,581.97 |
| 六、净利润 | 420,436,301.43 | 275,203,101.22 | 195,250,686.39 | 880,918,419.54 |
| 持续经营净利润 | 420,436,301.43 | 275,203,101.22 | 195,250,686.39 | 880,918,419.54 |
| 归属于母公司股东的净利润 | 423,655,185.12 | 277,508,333.27 | 196,529,798.71 | 889,537,704.85 |
| 少数股东损益 | -3,218,883.69 | -2,305,232.05 | -1,279,112.32 | -8,619,285.31 |
| (一)基本每股收益 | 0.53 | 0.35 | 0.25 | 1.12 |
| (二)稀释每股收益 | 0.52 | 0.34 | 0.24 | 1.13 |
| 八、其他综合收益 | 0 | 0 | 0 | -33,166,377.43 |
| 归属于母公司股东的其他综合收益 | 0 | 0 | 0 | -33,166,377.43 |
| 九、综合收益总额 | 420,436,301.43 | 275,203,101.22 | 195,250,686.39 | 847,752,042.11 |
| 归属于母公司股东的综合收益总额 | 423,655,185.12 | 277,508,333.27 | 196,529,798.71 | 856,371,327.42 |
| 归属于少数股东的综合收益总额 | -3,218,883.69 | -2,305,232.05 | -1,279,112.32 | -8,619,285.31 |
| 公告日期 | 2023-10-28 | 2023-08-19 | 2023-04-28 | 2023-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |